Chemotherapy
ERC1671 + GM-CSF + Cyclophosphamide for Glioblastoma
Recruiting0 awardsPhase 2
Orange, California
This trial looks at a new treatment for glioblastoma and gliosarcoma (both brain cancer) that includes the drug ERC1671. It is compared to the standard treatment, which is just bevacizumab (a different drug).
ACE Inhibitor
Ramipril for Memory Loss in Glioblastoma Patients
Recruiting1 awardPhase 2
Los Angeles, California
This trial is testing whether Ramipril can help cancer patients undergoing chemoradiation treatment by reducing memory loss. Patients will take the drug throughout treatment and for four months after. Memory will be assessed using neurocognitive tests.
Popular Filters
Trials for GBM Patients
Topoisomerase I inhibitors
Lurbinectedin + Irinotecan for Cancer
Recruiting2 awardsPhase 1 & 2
Boston, Massachusetts
This trial is testing a new cancer drug, Lurbinectedin, in combination with another cancer drug, irinotecan. The trial will have two parts: first, they will test different doses of the drugs to see what is safe; then, they will expand the trial to include more people.
Alkylating agents
Vaccine Therapy + Temozolomide for Glioblastoma
Recruiting1 awardPhase 2
Boston, Massachusetts
This trial studies how well a special vaccine works with a common chemotherapy drug in treating patients with recently found brain cancer. The vaccine helps the immune system fight the cancer, while the chemotherapy attacks the cancer cells directly.
Cancer Vaccine
Personalized Cancer Vaccine + RT + Pembrolizumab for Glioblastoma
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is studying a new type of vaccine as a possible treatment for patients with glioblastoma. It is evaluating the safety of the vaccine and finding the right dose to use.
Trials for Pituitary Adenomas Patients
Monoclonal Antibodies
Intra-arterial Cetuximab for Newly Diagnosed Glioblastoma
Recruiting3 awardsPhase 1 & 2
New York, New York
This trial is a study to see if a new treatment for brain cancer is safe and effective. The new treatment is a combination of standard chemotherapy and radiation therapy, with an additional drug given through a direct infusion into the brain.
Alkylating agents
Pembrolizumab + Temozolomide + TTFields for Glioblastoma
Recruiting1 awardPhase 2
Gainesville, Florida
This trial is testing whether adding pembrolizumab to the standard treatment for glioblastoma (surgery, radiation, and chemotherapy) can help patients live longer without their disease progressing.
Trials for MET Positive Patients
Cancer Vaccine
Personalized Cancer Vaccine + RT + Pembrolizumab for Glioblastoma
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is studying a new type of vaccine as a possible treatment for patients with glioblastoma. It is evaluating the safety of the vaccine and finding the right dose to use.
Alkylating agents
Pembrolizumab + Temozolomide + TTFields for Glioblastoma
Recruiting1 awardPhase 2
Gainesville, Florida
This trial is testing whether adding pembrolizumab to the standard treatment for glioblastoma (surgery, radiation, and chemotherapy) can help patients live longer without their disease progressing.
Alkylating agent
Immunotherapy + Targeted Therapy + Radiation for Glioblastoma
Recruiting2 awardsPhase 1
Chicago, Illinois
This trial is testing a combination of immunotherapy and targeted therapy with radiation therapy, with or without chemotherapy, to see if it is more effective than standard radiation therapy with or without chemotherapy in treating patients with newly diagnosed glioblastoma.
Trials for MGMT Positive Patients
Alkylating agent
OKN-007 + Temozolomide for Glioblastoma
Recruiting1 awardPhase 1
Oklahoma City, Oklahoma
This trial is testing if adding the drug OKN-007 to the standard treatment with Temozolomide and radiotherapy can help patients with malignant Glioblastoma, especially those whose cancer has gotten worse after initial treatment. Temozolomide has become a cornerstone in the treatment of glioblastoma, often used in combination with radiotherapy.
Trials With No Placebo
Topoisomerase I inhibitors
Lurbinectedin + Irinotecan for Cancer
Recruiting2 awardsPhase 1 & 2
Boston, Massachusetts
This trial is testing a new cancer drug, Lurbinectedin, in combination with another cancer drug, irinotecan. The trial will have two parts: first, they will test different doses of the drugs to see what is safe; then, they will expand the trial to include more people.
Alkylating agents
Vaccine Therapy + Temozolomide for Glioblastoma
Recruiting1 awardPhase 2
Boston, Massachusetts
This trial studies how well a special vaccine works with a common chemotherapy drug in treating patients with recently found brain cancer. The vaccine helps the immune system fight the cancer, while the chemotherapy attacks the cancer cells directly.
Cancer Vaccine
Personalized Cancer Vaccine + RT + Pembrolizumab for Glioblastoma
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is studying a new type of vaccine as a possible treatment for patients with glioblastoma. It is evaluating the safety of the vaccine and finding the right dose to use.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.